Coronary artery disease (CAD) is the leading cause of death in the world. Myocardial perfusion imaging (MPI) plays a significant role in non-invasive diagnosis and prognosis of CAD. However, neither single-photon emission computed tomography nor positron emission tomography clinical MPI agents can absolutely satisfy the demands of clinical practice. In the past decades, tremendous developments happened in the field of F-18-labeled MPI tracers. This review summarizes the current state of F-18-labeled MPI tracers, basic research data of those tracers, and the future direction of MPI tracer research.
基金：
National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81301251, 81471707]
第一作者机构：[1]Capital Med Univ, Dept Nucl Med, Beijing Anzhen Hosp, Beijing 100029, Peoples R China;
通讯作者：
通讯机构：[2]Xiamen Univ, State Key Lab Mol Vaccinol & Mol Diagnost, Sch Publ Hlth, Xiamen 361102, Peoples R China;[3]Xiamen Univ, Ctr Mol Imaging & Translat Med, Sch Publ Hlth, Xiamen 361102, Peoples R China
推荐引用方式(GB/T 7714)：
Mou Tiantian,Zhang Xianzhong.Research Progress on F-18-Labeled Agents for Imaging of Myocardial Perfusion with Positron Emission Tomography[J].MOLECULES.2017,22(4):-.doi:10.3390/molecules22040562.
APA：
Mou, Tiantian&Zhang, Xianzhong.(2017).Research Progress on F-18-Labeled Agents for Imaging of Myocardial Perfusion with Positron Emission Tomography.MOLECULES,22,(4)
MLA：
Mou, Tiantian,et al."Research Progress on F-18-Labeled Agents for Imaging of Myocardial Perfusion with Positron Emission Tomography".MOLECULES 22..4(2017):-
